-
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
Not Recruiting
More
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet
known if giving radiation therapy to the head is effective in preventing CNS metastases in
patients who have stage III non-small cell lung cancer.
PURPOSE: This randomized phase III trial is studying how well radiation therapy to the head
works in preventing CNS metastases in patients who have been previously treated for stage III
non-small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Derek Huang, 6507250203.
Stanford Investigators
View full details
-
Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer
Not Recruiting
More
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. This may be an
effective treatment for extensive stage small cell lung cancer.
PURPOSE: This randomized phase II trial is comparing how well radiation therapy to the brain
works when given with or without radiation therapy to other areas of the body in treating
patients with extensive stage small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laura Gable, 6507360798.
Stanford Investigators
View full details
-
Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
Recruiting
More
The purpose of this study is to identify and confirm new blood and tissue markers for
prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has
been shown to increase the risk of tumor spread and enhance tumor resistance to the standard
treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently
identified several proteins or markers in the blood and in tumors (including osteopontin,
lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that
may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.
Lead Sponsor
Stanford Investigators
View full details
-
Endoscopic Capillary Oximetry for Tumor Diagnosis in Head and Neck Cancer
Not Recruiting
More
Endoscopy is a standard part of the evaluation of patients with head and neck cancer used for
determining the extent of tumor involvement. However, not all areas involved by tumor are
apparent visually. Preliminary results indicate that compared with normal tissues, tumors
have abnormal levels of capillary oxygenation. The purpose of this study is to determine the
ability of non-pulsatile visible light tissue oxygen monitoring to differentiate normal and
tumor tissue based on capillary oxygenation during endoscopy Should this be possible, this
method could be used to mark tumor extent and invasion, even when that invasion is up to 5mm
blow the tissue surface.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peter Maxim, 6507243018.
Lead Sponsor
Stanford Investigators
View full details
-
CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy
Not Recruiting
More
This study assesses computed tomography (CT) perfusion imaging in predicting treatment
response in patients with non-small cell lung cancer or tumors that have spread from the
primary site (place where it started) to the lungs (metastases) treated with stereotactic
ablative radiation therapy. CT perfusion imaging is a special type of CT that uses an
injected dye in order to see how blood flow through tissues, including lung tissue. CT
perfusion imaging of the lungs may help doctors learn whether perfusion characteristics of
lung tumors may be predictive of response to treatment and whether lung perfusion
characteristics can be used to follow response to treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Samantha Wong, 650-498-8495.
Lead Sponsor
Stanford Investigators
View full details
-
Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
Recruiting
More
The purpose of this study is to measure the levels of serum proteins and other biomarkers in
cancer patients and in patients suspected of having cancer. We believe that some of these
markers may be useful for confirming the diagnosis or for selecting patients for specific
types of cancer therapies. These markers may also help to predict response to therapy,
relapse after therapy, and survival after therapy.
Lead Sponsor
Stanford Investigators
View full details
-
Evaluation of Cyberknife Precision Radiation Delivery System for Unresectable Malignant Lung Cancer
Not Recruiting
More
This study has two primary objectives. The first objective is to determine the maximal
tolerated dose (MTD) that can be delivered with stereotactic radiosurgery in patients with
inoperable malignant lung tumors. Once the MTD is established, the second objective is to
determine the efficacy of radiosurgical ablation of lung tumors in terms of symptoms and
radiographic responses.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Lead Sponsor
Stanford Investigators
View full details
-
4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy
Not Recruiting
More
To develop and investigate a novel radiotherapy technique for preserving lung function based
on a map of lung function.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laura Gable, 650-736-0798.
Stanford Investigators
View full details
-
Cervical Nodal Mets in Squamous Cell Carcinoma of H&N - MRI, FDG-PET, & Histopathologic Correlation
Not Recruiting
More
The purpose of this study is to determine the value of novel non-invasive medical imaging
methods for detecting the spread of head and neck squamous cell carcinoma to the lymph nodes
in the neck by comparing their results to findings at the time of surgery.
Stanford is currently not accepting patients for this trial.
For more information, please contact Quynh-Thu Le, 6504986184.
Lead Sponsor
Stanford Investigators
View full details
-
Radical-Dose Image Guided Radiation Therapy in Treating Patients With Metastatic Non-small Cell Lung Cancer Undergoing Immunotherapy
Not Recruiting
More
This phase II trial studies how well radical-dose image guided radiation therapy works in
treating patients with non-small cell lung cancer that has spread to other places in the body
who are undergoing immunotherapy. Radiation therapy uses high energy x-rays to kill tumor
cells and shrink tumors. Giving radical-dose image guided radiation therapy to patients with
non-small cell lung cancer may help to improve response to immunotherapy anti-cancer
treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Kim Nguyen, 650-497-8966.
Lead Sponsor
Stanford Investigators
View full details
-
Indirect Magnetic Resonance Lymphangiography of the Head and Neck Region Using Conventional Gadolinium-based Contrast
Not Recruiting
More
To determine the ability of magnetic resonance lymphangiography using conventional gadolinium
injected directly into the tumor site and PET scan in detecting microscopic nodal metastasis
in patients with newly diagnosed H&N cancers
Stanford is currently not accepting patients for this trial.
For more information, please contact Bill Loo, 6507367143.
Lead Sponsor
Stanford Investigators
View full details
-
BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Not Recruiting
More
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells.
Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some
block the ability of tumor cells to grow and spread. Others find tumor cells and help kill
them or carry tumor-killing substances to them. Drugs used in chemotherapy work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving vaccine
therapy together with bevacizumab after chemotherapy and radiation therapy may kill more
tumor cells.
PURPOSE: This phase II trial is studying the side effects of giving BLP25 liposome vaccine
together with bevacizumab after chemotherapy and radiation therapy in treating patients with
newly diagnosed stage IIIA or stage IIIB non-small cell lung cancer that cannot be removed by
surgery.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Pitsiouni, 650-721-6977.
Stanford Investigators
View full details
-
High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Not Recruiting
More
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in
chemotherapy, such as paclitaxel, carboplatin work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal
antibodies, such as cetuximab can block tumor growth in different ways. Some block the
ability of tumor cells to grow and spread. Others find tumor cells and help kill them or
carry tumor-killing substances to them. It is not yet known whether high-dose radiation
therapy is more effective than standard-dose radiation therapy when given together with
combination chemotherapy with or without cetuximab in treating patients with non-small cell
lung cancer.
PURPOSE: This randomized phase III trial is studying high-dose or standard-dose radiation
therapy given together with chemotherapy with or without cetuximab to see how well they work
in treating patients with newly diagnosed stage III non-small cell lung cancer that cannot be
removed by surgery.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laura Gable, 6507360798.
Stanford Investigators
View full details
-
CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer
Not Recruiting
More
The purpose of this study is to assess the short and long-term outcomes after CyberKnife
stereotactic radiosurgery for early stage non-small cell lung cancer (NSCLC) in patients who
are medically inoperable.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Stanford Investigators
View full details
-
Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer
Not Recruiting
More
RATIONALE: Manuka honey may prevent or reduce esophagitis-related pain caused by chemotherapy
and radiation therapy. It is not yet known whether Manuka honey is more effective than
standard care in preventing pain.
PURPOSE: This randomized phase II clinical trial is studying Manuka honey to see how well it
works in preventing esophagitis-related pain in patients receiving chemotherapy and radiation
therapy for lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laura Gable, 6507360798.
Stanford Investigators
View full details
-
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
Not Recruiting
More
Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy,
such as etoposide, carboplatin and cisplatin, work in different ways to stop the growth of
tumor cells, either by killing the cells or by stopping them from dividing. It is not yet
known which radiation therapy regimen is more effective when given together with chemotherapy
in treating patients with limited-stage small cell lung cancer. This randomized phase III
trial is comparing different chest radiation therapy regimens to see how well they work in
treating patients with limited-stage small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Katie Brown, 650-723-1423.
Stanford Investigators
View full details
-
Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Stage I Non-Small Cell Lung Cancer
Not Recruiting
More
RATIONALE: Surgery with or without internal radiation therapy may be an effective treatment
for non-small cell lung cancer. Internal radiation uses radioactive material placed directly
into or near a tumor to kill tumor cells. Stereotactic body radiation therapy may be able to
send x-rays directly to the tumor and cause less damage to normal tissue. It is not yet known
whether stereotactic body radiation therapy is more effective than surgery with or without
internal radiation therapy in treating non-small cell lung cancer.
PURPOSE: This randomized phase III trial is studying how well surgery with or without
internal radiation therapy works compared with stereotactic body radiation therapy in
treating patients with high-risk stage IA or stage IB non-small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Stanford Investigators
View full details
-
Specialized Radiation Therapy in Treating Patients With Stage II, Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer and Poor Performance Status
Not Recruiting
More
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to
the tumor may kill more tumor cells and cause less damage to normal tissue.
PURPOSE: This phase I trial is studying the side effects and best dose of specialized
radiation therapy in treating patients with stage II, stage III, stage IV, or recurrent
non-small cell lung cancer and poor performance status.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laura Gable, 6507360798.
Stanford Investigators
View full details
-
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
Not Recruiting
More
Lung cancer remains the most frequent cause of cancer death in both men and women in the
world. Surgical resection using lobectomy with mediastinal lymph node dissection or sampling
has been a standard of care for operable early stage NSCLC. Several studies have reported
high local control and survival using SBRT in stage I NSCLC patients. SBRT is now an accepted
treatment for medically inoperable patients with stage I NSCLC and patients with operable
stage I lung cancer are entered on clinical protocols. The purpose of this study is to
conduct a phase III randomized study to compare CyberKnife SBRT with surgery, the current
standard of care for stage I operable NSCLC.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Stanford Investigators
View full details
-
Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC
Not Recruiting
More
The purpose of this study is to assess how well this particular combination of chemotherapy,
radiation and surgery works to help people with locally advanced lung cancer, how well PET
scans indicates whether someone has responded to chemotherapy and radiation, and gene
expression patterns related to outcomes in patients with locally advanced lung cancer who
receive this treatment regimen.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lisa Zhou, 6507364112.
Lead Sponsor
Stanford Investigators
View full details
-
Pulmonary Interstitial Lymphography in Early Stage Lung Cancer
Not Recruiting
More
The stereotactic body radiation therapy (SBRT) procedure is an emerging alternative to the
standard treatment for early stage non-small cell lung cancer (NSCLC), typically lobectomy
with lymphadenectomy. This procedure (lobectomy) does not fulfill the medical need as many
patients are poor operative candidates or decline surgery.
This study assesses the feasibility of stereotactic body radiation therapy (SBRT) as a tool
to produce therapeutically useful computed tomography (CT) scans, using standard
water-soluble iodinated compounds as the contrast agents.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laura Gable, 6507360798.
Lead Sponsor
Stanford Investigators
View full details
-
The Role of Audiovisual Biofeedback on Image Quality During 4D Anatomic and Functional Imaging
Not Recruiting
More
This study will investigate whether audiovisual biofeedback, in which visual and audio cues
are used to regulate the patient's breathing, can increase the image quality of 4D CT and 4D
PET scans.
Stanford is currently not accepting patients for this trial.
For more information, please contact SPECTRUM, .
Lead Sponsor
Stanford Investigators
View full details
-
Molecular Analysis of Thoracic Malignancies
Recruiting
More
A research study to learn about the biologic features of cancer development, growth, and
spread. We are studying components of blood, tumor tissue, normal tissue, and other fluids,
such as urine, cerebrospinal fluid, abdominal or chest fluid in patients with cancer. Our
analyses of blood, tissue, and/or fluids may lead to improved diagnosis and treatment of
cancer by the identification of markers that predict clinical outcome, markers that predict
response to specific therapies, and the identification of targets for new therapies.
Lead Sponsor
Stanford Investigators
View full details
-
Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer
Not Recruiting
More
This randomized phase II trial studies how well positron emission tomography (PET)/computed
tomography (CT)-guided radiation therapy works compared to standard radiation therapy in
treating patients with stage III non-small cell lung cancer. Radiation therapy uses
high-energy x-rays to kill tumor cells. Using imaging procedures, such as PET and CT scans,
to guide the radiation therapy, may help doctors deliver higher doses directly to the tumor
and cause less damage to healthy tissue.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laura Gable, 650-736-0798.
Stanford Investigators
View full details
-
Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Not Recruiting
More
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized
radiation therapy that delivers a high dose of radiation directly to the tumor may kill more
tumor cells and cause less damage to normal tissue. It is not yet known which regimen of
stereotactic body radiation therapy is more effective in treating patients with non-small
cell lung cancer.
PURPOSE: This randomized phase II trial is studying the side effects of two radiation therapy
regimens and to see how well they work in treating patients with stage I non-small cell lung
cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact laura gable, 6507360798.
Stanford Investigators
View full details
-
SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer
Not Recruiting
More
The SABR-ATAC trial (Stereotactic Ablative Radiotherapy and anti-TGFB Antibody Combination)
is a phase I/II trial that studies the side effects and efficacy of fresolimumab, an
anti-transforming growth factor beta (TGFB) antibody, when given with stereotactic ablative
radiotherapy in patients with stage IA-IB non-small cell lung cancer. Fresolimumab may
inhibit radiation side effects and block tumor growth through multiple mechanisms.
Stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiotherapy
(SBRT), is a specialized form of radiation therapy that precisely delivers high dose
radiation directly to tumors, thus killing tumor cells and minimizing damage to normal
tissue. Giving fresolimumab with SABR may work better in treating patients with early stage
non-small cell lung cancer than treating with SABR alone.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laura Gable, 650-736-0798.
Stanford Investigators
View full details
-
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
Not Recruiting
More
This randomized phase II trial studies how well erlotinib hydrochloride or crizotinib with
chemoradiation therapy works in treating patients with stage III non-small cell lung cancer.
Radiation therapy uses high energy x rays to kill tumor cells. Specialized radiation therapy
that delivers a high dose of radiation directly to the tumor may kill more tumor cells and
cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin, etoposide,
paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading. It
is not yet known whether giving erlotinib hydrochloride is more effective than crizotinib
with chemoradiation therapy in treating patients with non-small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Katie Brown, 650-723-1423.
Stanford Investigators
View full details
-
Imaging and Biomarkers of Hypoxia in Solid Tumors
Not Recruiting
More
Hypoxia, meaning a lack of oxygen, has been associated strongly with a wide range of human
cancers. Hypoxia occurs when tumor growth exceeds the ability of blood vessels to supply the
tumor with oxygenated blood. It is currently understood that hypoxic tumors are more
aggressive. Current methods for measuring hypoxia include invasive procedures such as tissue
biopsy, or insertion of an electrode into the tumor. EF5-PET may be a non-invasive way to
measure tumor hypoxia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Justin Carter, 650-725-4796.
Lead Sponsor
Stanford Investigators
- Heather Wakelee
- Quynh-Thu Le, MD
- Edward Graves
- John B. Sunwoo, MD
- Joseph Shrager
- Maximilian Diehn, MD, PhD
- Edward J. Damrose, MD, FACS
- Michael J. Kaplan, MD
- Amato J. Giaccia
- A. Dimitrios Colevas, MD
- Billy W Loo, Jr, MD PhD FASTRO FACR
View full details
-
Feasibility of Using Real-time Cine-MRI for Treating Moving & Deforming Tumors
Not Recruiting
More
This study aims to investigate and optimize imaging sequences and parameters of rapid
real-time MRI in order to obtain adequate guidance for accurately and precisely delivering
radiation to moving abdominal and thoracic tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melody Chung, 6507360798.
Lead Sponsor
Stanford Investigators
View full details
-
The Role of FDG PET in Radiation Treatment Planning for Head and Neck Cancers
Not Recruiting
More
In patients with cancer of the head and neck and rectum, knowing the exact location of the
tumor is important for designing the radiation field to ensure delivery of high dose of
radiation to the tumor while sparing surrounding normal tissues. A new medical imaging method
which is a combination of positron emission tomography (PET) and computed tomography (CT)
scan, has shown promise in helping the radiation oncologist in defining the exact location
and extent of the tumor in certain cancers such as lung cancers. Therefore the purpose of
this study is to determine if these imaging methods can be used in combination with the
standard radiation treatment planning procedure to improve the accuracy to targeting your
tumor with radiation. In addition the PET-CT scan, similar to the PET scan alone with better
resolution, can be used to determine whether the tumor has spread to any part of the body
outside of the head and neck sites.
Stanford is currently not accepting patients for this trial.
For more information, please contact Quynh-Thu Le, 6504986184.
Lead Sponsor
Stanford Investigators
View full details
-
Breath Analysis for Evaluation of Radiation Exposure in Lung Cancer Patients Treated With Radiation
Not Recruiting
More
Patients treated with radiation therapy for lung tumors can experience inflammation after
treatment. This study hopes to evaluate the use of breath analysis to evaluate changes in the
composition of exhaled breath in patients undergoing radiotherapy. If changes can be
detected, this may ultimately serve as biomarkers for identifying patients at highest risk
for radiation-induced lung injury (radiation pneumonitis).
Stanford is currently not accepting patients for this trial.
For more information, please contact Laura Gable, 6507360798.
Lead Sponsor
Stanford Investigators
View full details
-
Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers
Not Recruiting
More
The purpose of this study is to study the effect of the drug DCA (dichloroacetate) on
recurrent head and neck cancers. Part of this study will also use EF5 PET scan to study tumor
hypoxia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alice Banh, 650-723-1423.
Stanford Investigators
View full details
-
Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)
Not Recruiting
More
A research study of a procedure to treating lung cancer with focused radiation called
Stereotactic Ablative Radiotherapy (SABR). The purpose of this study is to evaluate the
effectiveness of individualizing the dose of radiation used to treat lung tumors with SABR
based on tumor-specific factors.
While recent research has identified SABR as a promising method to increase local control
(LC) of lung cancer, further research has indicated that tumor volume is a prognostic factor,
with increased size/volume of tumor being associated with poorer outcomes. This study
explores if a volume-adapted strategy for the radiologic exposure (dose) will improve
efficacy in larger tumors (ie, > 10 cc).
This is a study of the procedure stereotactic ablative radiotherapy (SABR). It is not a study
of a specific drug or device.
Stanford is currently not accepting patients for this trial.
For more information, please contact Samantha Wong, 650-498-8495.
Lead Sponsor
Stanford Investigators
View full details
-
A Longitudinal Study of Plasma EBV DNA in Nasopharyngeal Carcinoma From Both Endemic and Non-Endemic Patient Populations
Not Recruiting
More
1. To determine the prognostic implication of plasma Epstein-Bar Virus (EBV) DNA
concentrations, as measured by quantitative polymerase chain reaction (PCR) in patients
with nasopharyngeal carcinoma (NPC).
2. To relate pretreatment plasma EBV DNA concentration to WHO classification of these
tumors both in endemic and non-endemic areas.
3. To determine whether pretreatment plasma EBV DNA can serve as a prognostic factor for
both endemic and non-endemic patient populations.
Stanford is currently not accepting patients for this trial.
For more information, please contact Quynh-Thu Le, 650-498-6184.
Lead Sponsor
Stanford Investigators
View full details
-
Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery
Not Recruiting
More
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the
tumor and cause less damage to normal tissue near the tumor.
PURPOSE: This phase II trial is studying how well stereotactic body radiation therapy works
in treating patients with stage I or stage II non-small cell lung cancer that can be removed
by surgery.
Stanford is currently not accepting patients for this trial.
For more information, please contact Melody Chung, 6507360798.
Stanford Investigators
View full details
-
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy (CT), such as paclitaxel and carboplatin, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Radiation therapy (RT) uses high-energy x-rays to kill tumor cells.
Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some
block the ability of tumor cells to grow and spread. Others find tumor cells and help kill
them or carry tumor-killing substances to them. Giving these treatments before surgery may
make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is
not yet known whether chemotherapy and radiation therapy are more effective when given with
or without panitumumab in treating patients with non-small cell lung cancer.
PURPOSE: This randomized phase II trial is studying chemotherapy and radiation therapy to see
how well they work when given with or without panitumumab in treating patients with stage
IIIA non-small cell lung cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Laura Gable, 6507360798.
Stanford Investigators
View full details